We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-coding Regions of the Genome in Microglia Linked to Alzheimer’s Disease Risk

By LabMedica International staff writers
Posted on 28 Nov 2019
A recently published paper linked risk of developing Alzheimer’s disease (AD) to enhancers - non-coding DNA regions of the genome - that were present in microglia but not in other types of brain cells such as neurons or astrocytes.

In genetics, an enhancer is a short (50–1500 base pair) region of DNA that can be bound by proteins (activators) to increase the likelihood that transcription of a particular gene will occur. More...
Enhancers can be located up to one million base pairs away from the target gene, upstream or downstream from the start site. There are hundreds of thousands of enhancers in the human genome.

Investigators at the University of California, San Diego (USA) isolated four different kinds of brain cells: neurons, microglia, oligodendrocytes, and astrocytes from six AD patients. The genes in these cells were examined for genetic variations associated with the disease in non-coding enhancer regions of each cell type.

Results revealed that while psychiatric disorders were primarily associated with variants in transcriptional enhancers and promoters in neurons, sporadic AD variants were largely confined to microglia enhancers. Interactome maps (maps of the whole set of molecular interactions in a particular cell) connected disease-risk variants in cell type-specific enhancers to promoters in an extended microglia gene network in AD.

Microglia are a type of neuroglia located throughout the brain and spinal cord. Microglia account for 10 to 15% of all cells found within the brain. As the resident macrophage cells, they act as the first and main form of active immune defense in the central nervous system.

Employing pluripotent human stem cells, the investigators were able to target an enhancer region near BIN1, a gene previously been linked to AD. They found that deleting this enhancer region led to a dramatic reduction in expression of BIN1 in microglia, but not in neurons or astrocytes.

"Focusing on genetic variation associated with Alzheimer's disease (AD), we show preferential enrichment in disease risk variants in enhancers that are selectively active in microglia, the major immune cell in the brain," said senior author Dr. Christopher Glass, professor of cellular and molecular medicine at the University of California, San Diego. "This finding substantially extends prior studies linking microglia to late-onset Alzheimer's disease."

The paper was published in the November, 14, 2019, online edition of the journal Science.

Related Links:
University of California, San Diego


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Urinalysis Solution
UN-9000
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.